Insulin resistance is associated with the metabolic syndrome and is not directly linked to coronary artery disease

Clinica Chimica Acta

Volumn 412, Issue 11-12, 2011, Pages 1003-1007

  Vonbank, Alexander ^a,b,c   Saely, Christoph H ^a,b,c   Rein, Philipp ^a,b,c   Beer, Stefan ^a,b,c   Breuss, Johannes ^a,c   Boehnel, Christian ^a,c   Drexel, Heinz ^a,b,c,d  

^a Vorarlberg Institute for Vascular Investigation and Treatment VIVIT   (Austria)

^b ACADEMIC TEACHING HOSPITAL FELDKIRCH   (Austria)

^c PRIVATE UNIVERSITY OF THE PRINCIPALITY OF LIECHTENSTEIN   (Liechtenstein)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Atherothrombosis; Coronary angiography; Coronary artery disease; Coronary atherosclerosis; HOMA index; Insulin resistance; Metabolic syndrome

Indexed keywords

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; SCORING SYSTEM; SEX DIFFERENCE;

AGED; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 79955006382     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2011.02.008     Document Type: Article

References (41)

1. Sakkinen P.A., Wahl P., Cushman M., Lewis M.R., Tracy R.P. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000, 152:897-907.
2. Meigs J.B. Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 2000, 152:908-911.
3. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
4. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
5. Hu G., Qiao Q., Tuomilehto J. The metabolic syndrome and cardiovascular risk. Curr Diab Rev 2005, 1:137-143.
6. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709-2716.
7. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diab Care 2001, 24:683-689.
8. Ridker P.M., Buring J.E., Cook N.R., Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003, 107:391-397.
9. Arca M. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. Drugs 2007, 67(Suppl 1):43-54.
10. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709-2716.
11. Petersen J.L., Yow E., AlJaroudi W., et al. Metabolic syndrome is not associated with increased mortality or cardiovascular risk in nondiabetic patients with a new diagnosis of coronary artery disease. Circ Cardiovasc Qual Outcomes 2010, 3:165-172.
12. Klein B.E., Klein R., Lee K.E. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diab Care 2002, 25:1790-1794.
13. Saely C.H., Koch L., Schmid F., et al. Adult Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. Diab Care 2006, 29:901-907.
14. Saely C.H., Rein P., Drexel H. The metabolic syndrome and risk of cardiovascular disease and diabetes: experiences with the new diagnostic criteria from the International Diabetes Federation. Horm Metab Res 2007, 39:642-650.
15. Saely C.H., Aczel S., Marte T., Langer P., Hoefle G., Drexel H. The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metab 2005, 90:5698-5703.
16. Cheal K.L., Abbasi F., Lamendola C., McLaughlin T., Reaven G.M., Ford E.S. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 2004, 53:1195-1200.
17. Carr D.B., Utzschneider K.M., Hull R.L., et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004, 53:2087-2094.
18. Ascott-Evans B.H. The metabolic syndrome, insulin resistance and cardiovascular disease. SADJ 2005, 60:122-127.
19. Bonora E., Targher G., Formentini G., et al. The metabolic syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diab Med 2004, 21:52-58.
20. Bruno G., Merletti F., Biggeri A., et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diab Care 2004, 27:2689-2694.
21. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992, 326:242-250.
22. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992, 326:310-318.
23. Milani R.V., Lavie C.J. Prevalence and profile of metabolic syndrome in patients following acute coronary events and effects of therapeutic lifestyle change with cardiac rehabilitation. Am J Cardiol 2003, 92:50-54.
24. Scanlon P.J., Faxon D.P., Audet A.M., et al. ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol 1999, 33:1756-1824.
25. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
26. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
27. The IDF consensus worldwide definition of the metabolic syndrome [article online] Available from. http://www.idf.org/webdata/docs/metac_syndrome_def.pdf.
28. Drexel H., Amann F.W., Beran J., et al. Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation 1994, 90:2230-2235.
29. Saely C.H., Koch L., Schmid F., et al. Lipoprotein(a), type 2 diabetes and vascular risk in coronary patients. Eur J Clin Investig 2006, 36:91-97.
30. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
31. Hanley A.J., Karter A.J., Festa A., et al. Factor analysis of metabolic syndrome using directly measured insulin sensitivity: the Insulin Resistance Atherosclerosis study. Diabetes 2002, 51:2642-2647.
32. Solymoss B.C., Bourassa M.G., Campeau L., et al. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am J Cardiol 2004, 93:159-164.
33. Yavuz M.T., Yavuz O., Yazici M., et al. Interaction between Chlamydia pneumoniae seropositivity, inflammation and risk factors for atherosclerosis in patients with severe coronary stenosis. Scand J Clin Lab Investig 2006, 66:523-534.
34. Kasai T., Miyauchi K., Kubota N., et al. The relationship between the metabolic syndrome defined by various criteria and the extent of coronary artery disease. Atherosclerosis 2008, 197:944-950.
35. Takezako T., Saku K., Zhang B., Shirai K., Arakawa K. Insulin resistance and angiographical characteristics of coronary atherosclerosis. Jpn Circ J 1999, 63:666-673.
36. Sekiguchi M., Kurabayashi M., Adachi H., Hoshizaki H., Oshima S., Taniguchi K. Usefulness of insulin resistance measured by homeostasis model assessment in predicting restenosis after coronary stent placement in nondiabetic patients. Am J Cardiol 2004, 93:920-922.
37. Shinozaki K., Suzuki M., Ikebuchi M., Hara Y., Harano Y. Demonstration of insulin resistance in coronary artery disease documented with angiography. Diab Care 1996, 19:1-7.
38. Graner M., Syvanne M., Kahri J., Nieminen M.S., Taskinen M.R. Insulin resistance as predictor of the angiographic severity and extent of coronary artery disease. Ann Med 2007, 39:137-144.
39. Radke P.W., Voswinkel M., Reith M., et al. Relation of fasting insulin plasma levels to restenosis after elective coronary stent implantation in patients without diabetes mellitus. Am J Cardiol 2004, 93:639-641.
40. Ley C.J., Swan J., Godsland I.F., Walton C., Crook D., Stevenson J.C. Insulin resistance, lipoproteins, body fat and hemostasis in nonobese men with angina and a normal or abnormal coronary angiogram. J Am Coll Cardiol 1994, 23:377-383.
41. Galassi A.R., Tamburino C. Follow-up of patients undergoing percutaneous coronary intervention. Ital Heart J 2005, 6:530-539.